IFLI is supporting advances in understanding the biology of follicular lymphoma and accelerating the development of novel medicine to improve treatment and ultimately develop a cure.
Led by follicular lymphoma (FL) renowned experts, we aim at designing research programs to identify and understand the cellular and molecular determinants of tumor heterogeneity driving FL progression, treatment resistance, and transformation.
Identifying and validating surrogate or ancillary biomarkers to improve diagnostic, and disease progression prediction, inform treatment selection, allow response monitoring and decrease time on ineffective therapies.
Leveraging innovation in NGS to diagnose relapse before clinical or radiological evidence, optimize treatment response and inform treatment selection.
Gather clinical and multi-omics data, aggregate patient-reported outcomes to advance new biomarker and therapeutic target identification. Provide data access to researchers and interested third parties to support the rapid advance of drug development.
Identify the most promising technology platforms and partner with start-up/biotech companies to accelerate the development of novel therapies to benefit FL.
Filter by:
Thank you for your interest in contacting us. Please fill out the form with your inquiry or feedback, and our team will promptly respond to assist you.